69207-44-9

Usage

InChI:InChI=1/C5H5ClN2O/c1-8-5(9)4(6)2-3-7-8/h2-3H,1H3

Upstream product

• 933-76-6 4,5-dichloro-2-methyl-3(2H)-pyridazinone 
• 1075-08-7 4-Chloro-5-hydrazino-2-methyl-3(2H)-pyridazinone 
• 1677-79-8 4-chloropyridazin-3-ol 
• 74-88-4 methyl iodide 
• 1677-79-8 4-chloro-2,3-dihydropyridazin-3-one 

Downstream Products

• 874955-66-5 4-(2-aminophenyl)-2-methylpyridazin-3(2H)-one 
• 874955-65-4 2-methyl-4-(2-pivaloylaminophenyl)pyridazin-3(2H)-one 
• 98700-55-1 4-<(3-tert-Butyl-2-phenyl-1,3-oxazolidin-5-yl)methoxy>-2-methylpyridazin-3(2H)-one 

Relevant academic research and scientific papers

IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER

Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

PRC2 INHIBITORS

The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. (Formula (I))

Novel Series of Dihydropyridinone P2X7 Receptor Antagonists

Identification of singleton P2X7 inhibitor 1 from HTS gave a pharmacophore that eventually turned into potential clinical candidates 17 and 19. During development, a number of issues were successfully addressed, such as metabolic stability, plasma stability, GSH adduct formation, and aniline mutagenicity. Thus, careful modification of the molecule, such as conversion of the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper substitution at C-5″, and in some cases addition of fluorine atoms to the aniline ring allowed for the identification of a novel class of potent P2X7 inhibitors suitable for evaluating the role of P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders.